Kezar Life Sciences, Inc.
General ticker "KZR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $37.6M (TTM average)
Kezar Life Sciences, Inc. follows the US Stock Market performance with the rate: 13.2%.
Estimated limits based on current volatility of 1.0%: low 6.12$, high 6.25$
Factors to consider:
- Total employees count: 58 (-31.0%) as of 2023
- Top business risk factors: High R&D costs, Key executive dependency, Regulatory and compliance, Market competition, Insufficient funding
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.24$, 29.50$]
- 2025-12-31 to 2026-12-31 estimated range: [5.06$, 21.47$]
Financial Metrics affecting the KZR estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -15.47 <= 0.33
- Positive: Shareholder equity ratio, % of 80.81 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 16.77 > -0.66
Short-term KZR quotes
Long-term KZR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $7.00MM | $0.00MM |
| Operating Expenses | $71.16MM | $118.42MM | $90.61MM |
| Operating Income | $-71.16MM | $-111.42MM | $-90.61MM |
| Non-Operating Income | $2.92MM | $9.55MM | $6.87MM |
| Interest Expense | $1.19MM | $1.55MM | $1.59MM |
| R&D Expense | $51.01MM | $85.70MM | $65.74MM |
| Income(Loss) | $-68.24MM | $-101.87MM | $-83.74MM |
| Profit(Loss)* | $-68.24MM | $-101.87MM | $-83.74MM |
| Stockholders Equity | $269.87MM | $187.57MM | $116.92MM |
| Assets | $299.57MM | $221.24MM | $144.68MM |
| Operating Cash Flow | $-58.85MM | $-81.64MM | $-74.21MM |
| Capital expenditure | $1.58MM | $1.81MM | $0.03MM |
| Investing Cash Flow | $-91.39MM | $76.05MM | $80.43MM |
| Financing Cash Flow | $127.86MM | $0.64MM | $0.10MM |
| Earnings Per Share** | $-1.01 | $-1.40 | $-1.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.